Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 5 , Pages 651-661, October 2010

Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell–stimulatory capacity

  • Corbin Clawson, BS

      Affiliations

    • Department of Bioengineering, University of California San Diego, La Jolla, California, USA
    • These two authors contributed equally to this work.
    • ,
  • Chien-Tze Huang, BS

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California, USA
    • These two authors contributed equally to this work.
    • ,
  • Diahnn Futalan, BS

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California, USA
    • ,
  • Daniel Martin Seible, BS

      Affiliations

    • Department of Molecular, Cellular, and Developmental Biology, University of California Santa Barbara, Santa Barbara, California, USA
    • ,
  • Rebecca Saenz, BS, MS

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California, USA
    • Department of Biomedical Sciences, University of California San Diego, La Jolla, California, USA
    • ,
  • Marie Larsson, PhD

      Affiliations

    • Division of Molecular Virology, Department of Clinical and Experimental Medicine, Linköping University, Lindkoeping, Sweden
    • ,
  • Wenxue Ma, MD, PhD

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California, USA
    • ,
  • Boris Minev, MD

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California, USA
    • ,
  • Fiona Zhang, PhD

      Affiliations

    • Department of Mechanical Engineering, University of California Riverside, Riverside California, USA
    • ,
  • Mihri Ozkan, PhD

      Affiliations

    • Department of Electrical Engineering, University of California Riverside, Riverside, California, USA
    • ,
  • Cengiz Ozkan, PhD

      Affiliations

    • Department of Mechanical Engineering, University of California Riverside, Riverside California, USA
    • ,
  • Sadik Esener, PhD

      Affiliations

    • Department of NanoEngineering, University of California San Diego, La Jolla, California, USA
    • ,
  • Davorka Messmer, PhD

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California, USA
    • Corresponding Author InformationCorresponding author: Moores Cancer Center, University of California San Diego, La Jolla, California 92093-0815, USA.

Received 12 June 2009; accepted 6 March 2010. published online 29 March 2010.

Abstract 

Nanoparticles (NPs) are attractive carriers for vaccines. We have previously shown that a short peptide (Hp91) activates dendritic cells (DCs), which are critical for initiation of immune responses. In an effort to develop Hp91 as a vaccine adjuvant with NP carriers, we evaluated its activity when encapsulated in or conjugated to the surface of poly(d,l-lactic-co-glycolic) acid (PLGA) NPs. We found that Hp91, when encapsulated in or conjugated to the surface of PLGA-NPs, not only activates both human and mouse DCs, but is in fact more potent than free Hp91. Hp91 packaged within NPs was about fivefold more potent than the free peptide, and Hp91 conjugated to the surface of NPs was ∼20-fold more potent than free Hp91. Because of their capacity to activate DCs, such NP-Hp91 systems are promising as delivery vehicles for subunit vaccines against infectious disease or cancer.

From the Clinical Editor

In this paper, nanoparticle-based dendritic cell activating vaccines are described and discussed. The authors report that the presented PLGA NP based vaccine constructs increase the potency of the studied vaccine by up to 20-fold, making them promising as delivery vehicles for subunit vaccines against infectious diseases or cancer.

Key words: PLGA nanoparticles, Peptide conjugation, Immune stimulation, Dendritic cells, HMGB1

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work is supported by the U.S. Army Medical Research and Materiel Command under Agreement No. W81XWH-07-1-0412 (D.M.); 5 U54 CA119335 from the National Institutes of Health/National Cancer Institute, (S.E.), the Swedish Research Council (VR) AI52731 and the Swedish International Development Cooperation Agency (SIDA) and VINNMER (Vinnova) (M.L.).

 Corporate affiliations: Call/Recall Inc., Nanogen, Genoptix, OMM, Orimedix, and Ziva Corp. (S.E.). Corporate affiliations: Call/Recall Inc., Nanogen, Genoptix, OMM, Orimedix, and Ziva Corp. (S.E.).

PII: S1549-9634(10)00097-3

doi:10.1016/j.nano.2010.03.001

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 5 , Pages 651-661, October 2010

Article Tools

* Image Usage & Resolution